Limits...
PROX1 is a predictor of survival for gliomas WHO grade II.

Elsir T, Qu M, Berntsson SG, Orrego A, Olofsson T, Lindström MS, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A - Br. J. Cancer (2011)

Bottom Line: The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.Higher PROX1 protein was associated with poor outcome.In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology-Pathology, Karolinska Institutet, CCK R8:05, Karolinska University Hospital, S-17176 Stockholm, Sweden.

ABSTRACT

Background: The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs. PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas.

Methods: A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.

Results: Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.

Conclusion: PROX1 is a novel predictor of survival for grade II gliomas.

Show MeSH

Related in: MedlinePlus

(A) Kaplan–Meier estimates of postoperative survival by the variable PROX1 protein expression for all samples with <10%, 10–30% and >30% immunopositive tumour cells. (B) Kaplan–Meier estimates of survival by the variable PROX1 protein expression after dichotomisation of PROX1 into <10% and ⩾10% immunopositive tumour cells (P=0.0183, log-rank test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3111172&req=5

fig2: (A) Kaplan–Meier estimates of postoperative survival by the variable PROX1 protein expression for all samples with <10%, 10–30% and >30% immunopositive tumour cells. (B) Kaplan–Meier estimates of survival by the variable PROX1 protein expression after dichotomisation of PROX1 into <10% and ⩾10% immunopositive tumour cells (P=0.0183, log-rank test).

Mentions: Analysis of the prognostic significance of PROX1 using the Kaplan–Meier model showed that high PROX1 expression (>30% of the tumour cells) correlated with shorter overall survival, compared with lower PROX1 expression (10–30%, respectively, <10% of the tumour cells) (Figure 2A). Dichotomisation of the variable PROX1 expression into ⩽10% and >10% positive cells showed that PROX1 expression >10% was associated with statistically significant shorter overall survival (P=0.0183, log-rank test) (Figure 2B).


PROX1 is a predictor of survival for gliomas WHO grade II.

Elsir T, Qu M, Berntsson SG, Orrego A, Olofsson T, Lindström MS, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A - Br. J. Cancer (2011)

(A) Kaplan–Meier estimates of postoperative survival by the variable PROX1 protein expression for all samples with <10%, 10–30% and >30% immunopositive tumour cells. (B) Kaplan–Meier estimates of survival by the variable PROX1 protein expression after dichotomisation of PROX1 into <10% and ⩾10% immunopositive tumour cells (P=0.0183, log-rank test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3111172&req=5

fig2: (A) Kaplan–Meier estimates of postoperative survival by the variable PROX1 protein expression for all samples with <10%, 10–30% and >30% immunopositive tumour cells. (B) Kaplan–Meier estimates of survival by the variable PROX1 protein expression after dichotomisation of PROX1 into <10% and ⩾10% immunopositive tumour cells (P=0.0183, log-rank test).
Mentions: Analysis of the prognostic significance of PROX1 using the Kaplan–Meier model showed that high PROX1 expression (>30% of the tumour cells) correlated with shorter overall survival, compared with lower PROX1 expression (10–30%, respectively, <10% of the tumour cells) (Figure 2A). Dichotomisation of the variable PROX1 expression into ⩽10% and >10% positive cells showed that PROX1 expression >10% was associated with statistically significant shorter overall survival (P=0.0183, log-rank test) (Figure 2B).

Bottom Line: The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.Higher PROX1 protein was associated with poor outcome.In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology-Pathology, Karolinska Institutet, CCK R8:05, Karolinska University Hospital, S-17176 Stockholm, Sweden.

ABSTRACT

Background: The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs. PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas.

Methods: A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.

Results: Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.

Conclusion: PROX1 is a novel predictor of survival for grade II gliomas.

Show MeSH
Related in: MedlinePlus